📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 18:09
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Zenlabs Ethica Q1 Results: Revenue up 23.5% YoY to ₹14.18 Cr, Net Loss at ₹0.57 Cr
Zenlabs Ethica reported a revenue of ₹14.18 Cr for the quarter ended June 30, 2026, representing a 23.5% increase from ₹11.48 Cr in the same period last year. However, the company swung to a net loss of ₹0.57 Cr for the quarter, compared to a marginal profit of ₹0.03 Cr in June 2025. This loss was driven by total expenses of ₹14.73 Cr exceeding total income, largely due to a significant increase in stock-in-trade costs. With a market cap of only ₹17 Cr and a high debt-to-equity ratio of 1.29, the company's return to losses is a concern for its financial stability.
Confidence: HIGH
What changedThe company transitioned from a marginal profit in the previous year's quarter to a net loss, despite achieving higher top-line revenue.
Why it mattersFor a micro-cap company with existing debt and negative TTM earnings, the inability to maintain profitability during revenue growth indicates structural margin pressure in its pharmaceutical trading business.
Revenue (Q1 FY27): ₹14.18 CrNet Loss (Q1 FY27): ₹0.57 CrRevenue vs TTM Revenue: ~30.2%Debt-to-Equity Ratio: 1.29EPS (Q1 FY27): ₹-0.88
📅 Short termThe stock is likely to face downward pressure in the short term as the market reacts to the net loss and negative EPS.
📈 Long termThe long-term outlook remains limited unless the company can demonstrate consistent profitability and reduce its debt burden relative to its small net worth.
⚠ Risk flags
- High debt-to-equity ratio (1.29)
- Negative earnings per share
- Operating expenses exceeding total income
- Micro-cap liquidity risks
Key Highlights
Revenue from operations grew 23.5% YoY to ₹14.18 Cr from ₹11.48 Cr.
Net loss for the quarter stood at ₹0.57 Cr against a profit of ₹0.03 Cr in the year-ago period.
Total expenses rose to ₹14.73 Cr, representing 104% of total income for the quarter.
Finance costs saw a slight reduction to ₹0.16 Cr from ₹0.21 Cr YoY.
Basic and Diluted EPS turned negative at ₹-0.88 for the quarter.
👀 What to Watch
Investors should monitor the company's operating margins and inventory management, as the current trading model failed to translate higher revenue into profit. The high debt-to-equity ratio of 1.29 remains a key risk factor to watch in upcoming quarters.
Zenlabs Ethica Q1 Revenue Rises 23.5% YoY to ₹14.18 Cr; Swings to Net Loss of ₹0.57 Cr
Zenlabs Ethica reported a 23.5% YoY increase in revenue to ₹14.18 Cr for the quarter ended June 30, 2026. Despite the top-line growth, the company swung to a net loss of ₹0.57 Cr, compared to a profit of ₹0.03 Cr in the year-ago period. The loss was primarily driven by a significant increase in stock-in-trade expenses, which reached ₹4.76 Cr. With a high debt-to-equity ratio of 1.29 and a market cap of only ₹17 Cr, the company's return to profitability remains a key concern for investors.
Confidence: HIGH
What changedThe company transitioned from a marginal profit in the previous year to a net loss in Q1 FY27, despite achieving higher sales volumes.
Why it mattersFor a micro-cap company with significant debt (₹11 Cr) relative to its net worth (₹9 Cr), consistent losses could lead to liquidity constraints and further erosion of shareholder value.
Revenue (Q1 FY27): ₹1,417.66 lakhsNet Loss (Q1 FY27): ₹57.12 lakhsRevenue vs TTM Revenue: ~30.2%Debt-to-Equity Ratio: 1.29Stock-in-trade expense: ₹475.94 lakhs
📅 Short termThe stock may face downward pressure as the market reacts to the swing from profit to loss and the impact of rising operational expenses.
📈 Long termThe long-term outlook is cautious; the company needs to demonstrate a sustainable path to profitability and debt reduction in its pharmaceutical trading business.
⚠ Risk flags
- High debt-to-equity ratio (1.29)
- Volatility in inventory/stock-in-trade costs
- Micro-cap liquidity risk
- Negative EPS
Key Highlights
Revenue from operations increased to ₹1,417.66 lakhs from ₹1,147.72 lakhs YoY, a growth of 23.5%
Net loss for the quarter stood at ₹57.12 lakhs compared to a net profit of ₹3.33 lakhs in June 2025
Stock-in-trade expenses surged to ₹475.94 lakhs from a credit (reduction) of ₹183.01 lakhs in the previous year's quarter
Finance costs saw a slight reduction to ₹15.70 lakhs from ₹20.76 lakhs YoY
Basic and Diluted EPS turned negative at ₹(0.88) for the quarter
👀 What to Watch
Investors should monitor the company's ability to manage inventory costs and stabilize margins, as the current trading model is struggling to translate revenue growth into bottom-line profits.
Zenlabs Ethica Appoints V Nexxtra as Sole Distributor; Secures 5% Margin and 70% Sourcing Clause
Zenlabs Ethica Ltd has entered into a sole and exclusive domestic business agreement with V Nexxtra Lifesciences Private Limited for the marketing and distribution of its entire product portfolio. Under the agreement, V Nexxtra will bear all sales, marketing, and logistics expenses, paying Zenlabs a margin of 5% on Net Sales Value for FY 2026-27, rising to 5.5% in FY 2027-28. A critical clause requires the distributor to source at least 70% of its procurement value from Zenlabs Ethica group companies, ensuring captive demand for the company's manufacturing operations.
Confidence: HIGH
What changedThe company has transitioned its entire domestic sales and marketing operations to a third-party exclusive distributor, V Nexxtra Lifesciences.
Why it mattersThis move offloads significant operational expenditure (sales staff, logistics) to the partner while securing a fixed margin and guaranteed volume for group manufacturing facilities, which is vital for a company currently reporting a net loss of Rs 2 Cr.
Guaranteed Margin (FY27): 5%Target Margin (FY28 onwards): 5.5%Minimum Group Sourcing: 70%Credit Period: 75 daysTTM Revenue: Rs 47 Cr
📅 Short termThe stock may see positive sentiment as the market digests the reduction in operational overheads and the guaranteed margin structure.
📈 Long termThe structural shift to a 70% captive sourcing model could stabilize manufacturing utilization, though long-term growth now depends heavily on the distributor's execution capabilities.
⚠ Risk flags
- High dependency on a single distributor for entire domestic revenue
- Credit risk associated with a 75-day payment cycle
- Potential loss of direct market intelligence
Key Highlights
Appointed V Nexxtra Lifesciences as the sole and exclusive distributor for the entire Indian territory.
Guaranteed minimum margin of 5% on Net Sales Value for FY 2026-27, payable by the 10th of each month.
Mandatory 70% sourcing requirement from Zenlabs Ethica group companies for the distributor's total procurement.
Distributor to bear 100% of costs related to sales teams, warehouses, and distribution centers.
Credit period established at 75 days from the date of invoice.
👀 What to Watch
Watch for the 'minimum turnover' targets in upcoming quarterly results to estimate the absolute margin inflow. Investors should also monitor if this shift from direct sales to a margin-based model improves the current Operating Profit Margin of 3.8%.
Zenlabs Ethica Appoints Mr. Sanjay Dhir as Chief Financial Officer
Zenlabs Ethica Ltd has appointed Mr. Sanjay Dhir as the Chief Financial Officer (CFO) effective July 21, 2026. This move aims to fulfill statutory requirements under Section 203 of the Companies Act, 2013. The company, a micro-cap with a market capitalization of Rs 20 Cr, is currently loss-making with a TTM PAT of Rs -2 Cr. The new CFO will be responsible for managing financial operations and strengthening governance frameworks in a period where the company faces a high debt-to-equity ratio of 1.29.
Confidence: HIGH
What changedThe company has appointed a new Chief Financial Officer to lead its financial and compliance functions.
Why it mattersFor a micro-cap company with negative earnings and significant debt relative to its size, the CFO role is critical for financial restructuring and achieving profitability.
Effective Date: July 21, 2026Market Cap: Rs 20 CrTTM Revenue: Rs 47 CrDebt-to-Equity Ratio: 1.29Operating Profit Margin: 3.8%
📅 Short termThe market is likely to remain neutral as this is a regulatory-driven management appointment without immediate impact on cash flows.
📈 Long termThe long-term impact depends on the new CFO's ability to steer the company toward a turnaround from its current loss-making status.
⚠ Risk flags
- Company is currently loss-making (TTM PAT Rs -2 Cr)
- High debt-to-equity ratio of 1.29
- Small market capitalization leads to high volatility
Key Highlights
Appointment of Mr. Sanjay Dhir as CFO effective from July 21, 2026
Company reported TTM revenue of Rs 47 Cr against a net loss of Rs 2 Cr
Board meeting for the appointment concluded within 30 minutes on July 22, 2026
Current debt levels stand at Rs 11 Cr against a net worth of Rs 9 Cr
👀 What to Watch
Investors should monitor upcoming quarterly results to see if the new financial leadership can improve the thin operating profit margins (3.8%) and manage the company's debt obligations.
Zenlabs Ethica Appoints Sanjay Dhir as CFO Effective July 21, 2026
Zenlabs Ethica Ltd has appointed Mr. Sanjay Dhir as Chief Financial Officer (CFO) effective July 21, 2026, to comply with Section 203 of the Companies Act, 2013. The company is a micro-cap with a market capitalization of Rs 21 Cr and is currently facing financial pressure with a TTM net loss of Rs 2 Cr. Mr. Dhir's background in accounting and compliance will be critical as the company manages a Debt-to-Equity ratio of 1.29 and low operating margins of 3.8%.
Confidence: HIGH
What changedThe company has formally appointed a new Chief Financial Officer to lead its finance and compliance functions.
Why it mattersFor a micro-cap company with negative earnings and significant debt relative to its net worth, a dedicated CFO is essential for maintaining governance and executing any potential financial turnaround.
Effective Date: 21st July, 2026Market Cap: Rs 21 CrTTM Net Profit: Rs -2 CrDebt-to-Equity Ratio: 1.29TTM Revenue: Rs 47 Cr
📅 Short termThe appointment is an administrative necessity and is unlikely to impact the stock price in the immediate term.
📈 Long termThe new CFO's ability to stabilize financial operations and improve transparency is vital for the company's long-term viability given its current loss-making status.
⚠ Risk flags
- Loss-making TTM performance
- High Debt-to-Equity ratio (1.29)
- Micro-cap liquidity risks
Key Highlights
Appointment of Mr. Sanjay Dhir as CFO effective from July 21, 2026
Company reported a TTM net loss of Rs 2 Cr on revenue of Rs 47 Cr
Debt levels stand at Rs 11 Cr against a Net Worth of Rs 9 Cr
Appointment fulfills statutory requirements under Section 203 of the Companies Act, 2013
👀 What to Watch
Monitor upcoming quarterly results to see if the new financial leadership can improve operating margins (currently 3.8%) and manage the high debt-to-equity ratio of 1.29.
